The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017.

Journal of Hematology & Oncology
Ming YiKongming Wu

Abstract

Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor prognosis. The risk of AML is highly related to age. In the context of population aging, a comprehensive report presenting epidemiological trends of AML is evaluable for policy-marker to allocate healthy resources. This study was based on the Global Burden of Disease 2017 database. We analyzed the change trends of incidence rate, death rate, and disability-adjusted life year (DALY) rate by calculating the corresponding estimated annual percentage change (EAPC) values. Besides, we investigated the influence of social development degree on AML's epidemiological trends and potential risk factors for AML-related mortality. From 1990 to 2017, the incidence of AML gradually increased in the globe. Males and elder people had a higher possibility to develop AML. Developed countries tended to have higher age-standardized incidence rate and death rate than developing regions. Smoking, high body mass index, occupational exposure to benzene, and formaldehyde were the main risk factors for AML-related mortality. Notably, the contribution ratio of exposure to carcinogens was significantly increased in the low social-demographic index (SDI) region than in the high SDI re...Continue Reading

References

Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y ChelghoumX Thomas
Oct 5, 2006·Cancer·Barbara Deschler, Michael Lübbert
May 17, 2007·American Journal of Hematology·Ethan A Natelson
Dec 23, 2009·Seminars in Cancer Biology·Steven W Lane, D Gary Gilliland
Jun 22, 2010·American Journal of Clinical Oncology·Margaret M ByrneMichael C Cheung
Jun 30, 2010·Environmental Health : a Global Access Science Source·Abdul KhaladeJouni J K Jaakkola
Apr 27, 2011·International Journal of Cancer. Journal International Du Cancer·Ramya VaradarajanMeir Wetzler
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Sep 2, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Quan-Shun WangWei-Dong Han
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert
Nov 27, 2014·The New England Journal of Medicine·Giulio GenoveseSteven A McCarroll
Dec 18, 2014·Blood·Gert Ossenkoppele, Bob Löwenberg
Feb 11, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Manali I PatelKim F Rhoads
Sep 25, 2015·Science Translational Medicine·Thomas McKerrell, George S Vassiliou
Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T M KadiaH Kantarjian
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Sep 8, 2016·International Journal of Cancer. Journal International Du Cancer·Jenny N PoynterErica Warlick
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars BullingerHartmut Döhner
Jun 3, 2017·Leukemia & Lymphoma·Jonathan A Webster, Keith W Pratz
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Aug 25, 2017·Nature Reviews. Cancer·Megan E McNerneyMichelle M Le Beau
Dec 22, 2017·Risk Analysis : an Official Publication of the Society for Risk Analysis·Stacy Fiebelkorn, Clive Meredith
Jan 6, 2018·Journal of Hematology & Oncology·Xue Yang, Jianxiang Wang
Apr 29, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J Gibson, David P Steensma
Aug 7, 2018·Mayo Clinic Proceedings·David P Steensma
Aug 7, 2018·Lancet·Nicholas J ShortJorge E Cortes
Nov 15, 2018·Cancers·Mario LuppiAdriano Venditti
Nov 21, 2018·Biomarker Research·Runxia GuHui Wei
Dec 6, 2018·Journal of Hematology & Oncology·Mei WuXiongpeng Zhu
Feb 8, 2019·Experimental Hematology & Oncology·Pimjai NiparuckSuporn Chuncharunee

❮ Previous
Next ❯

Citations

Feb 7, 2021·BMJ Case Reports·Zenab Yusuf TambawalaFatheya Alawadi
Oct 31, 2020·Trends in Molecular Medicine·Rachel Culp-HillEric M Pietras
Apr 1, 2021·Technology in Cancer Research & Treatment·Yanli LaiGuifang OuYang
May 25, 2021·Current Fungal Infection Reports·Daiana MacedoGuillermo Garcia-Effron
Jul 12, 2021·Experimental Hematology & Oncology·Yiyi YaoHuafeng Wang
Oct 13, 2021·Bone Marrow Transplantation·Shaun R McCann

❮ Previous
Next ❯

Software Mentioned

maps
ggplot2
R
RcolorBrewer

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.